Back to List View Graph View

CAR-T cells

chimeric antigen receptor T (CAR-T) cell therapy is an adoptive immunotherapy in which a patient's own T lymphocytes are genetically engineered to express synthetic surface receptors — chimeric antigen receptors (CARs) — that redirect cytotoxic killing toward tumor cells expressing a specified antigen.

Where the papers sit

29 papers from the last 6 months study CAR-T cells directly · updated from PubMed 16 Nov 2026

  • CAR-T Exhaustion in Tumors

    T-cell exhaustion and hostile tumor microenvironments are central barriers to CAR-T potency, persistence, and antitumor activity. Cystine restriction, IL-15 superagonism, TNC-scFv armoring, and EpCAM bispecific engagers seek to sustain function or overcome heterogeneity. Local hydrogel delivery and biomarker profiling extend this work toward better solid-tumor targeting and response prediction. Spatial modeling and post-treatment care broaden the cluster across mechanistic, translational, and clinical settings.

    8 papers · 27.6%

  • CD19 CAR-T in B-Cell Cancer

    CD19 CAR-T therapy is moving from salvage treatment toward durable consolidation and broader real-world use in B-cell leukemia and lymphoma. Studies emphasize remission, overall response, long-term outcomes, and comparisons with historical controls, including locally produced donor-derived products. BTK inhibition may improve DLBCL sensitivity, while TIGIT-CD155 signaling emerges as a functional checkpoint. Myasthenia gravis and an in vivo phase I report broaden the clinical scope, but efficacy remains most established in B-cell malignancies.

    8 papers · 27.6%

  • Tumor Microenvironment Remodeling

    Tumor microenvironment remodeling is being used to improve CAR-T activity in glioblastoma and other resistant solid tumors. CD70- and B7-H3-targeted cells, radiopharmaceutical sensitization, and Regnase-1 targeting aim to alter immune suppression or tumor vulnerability. Endogenous immune compartments and spatially resolved screening are becoming important alongside direct CAR-T design. Injectable programming platforms and orthotopic models support translation, but the best combination of sensitization and cell therapy remains unresolved.

    7 papers · 24.1%

  • CAR-T Efficacy Mechanisms

    CAR-T design is being tuned to improve efficacy through costimulation, chemokine recruitment, stress-state selection, and metabolic control. CD28-ICOS signaling, CCL19/CCR7 pairing, and protease-activated receptors are tested to strengthen targeting or reshape the tumor context. Manufacturing also advances through sequential activation and nonviral large-payload knock-in. Divergent αβ and γδ T-cell fates and tumor-intrinsic stress responses leave open which signaling architectures best predict durable benefit.

    6 papers · 20.7%

PARADIGM SHIFT

CAR-T efficacy depends on remodeling and recruiting endogenous immunity, rather than on autonomous tumor killing alone

The recurrent glioblastoma study of intracerebroventricular bivalent CAR-T cells and the osteosarcoma study of Regnase-1-deficient B7-H3-CAR-T cells found that treatment outcome was determined in substantial part by host immune remodeling. In glioblastoma, responders showed expansion of cytotoxic natural killer cells, whereas nonresponders had regulatory T-cell expansion and suppressive myeloid cells; in osteosarcoma, Regnase-1 deletion enabled CAR-T cells to recruit interferon-γ-producing endogenous T cells and NK cells while reducing inhibitory myeloid cells (PMIDs 42296961, 42641597). This reverses an account in which CAR-T cells are principally autonomous cytotoxic effectors confronting a largely fixed tumor microenvironment: endogenous immune composition and CAR-T-induced ecosystem changes become therapeutic determinants and targets for optimization.

NEW DIRECTION

CAR-T cells are used to eliminate pathogenic hepatic stellate cells and treat liver fibrosis

The liver-fibrosis study of PAR1-targeted CAR-T cells used the cells against activated hepatic stellate cells rather than malignant or infected cells. In a carbon-tetrachloride mouse model, microbubble-enhanced delivery increased CAR-T penetration and retention in fibrotic liver, while elimination of PAR1-expressing stellate cells suppressed their activation and attenuated fibrosis progression 42385355Jul. This assigns CAR-T cells a tissue-remodeling antifibrotic role: selective removal of pathogenic stromal cells to reverse organ fibrosis rather than direct treatment of cancer or infected-cell disease.

Papers

The 29 papers from the last 6 months that study CAR-T cells directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

CAR-T Exhaustion in Tumors (8)
  1. Extracellular matrix-targeted TNC-scFv armoring enhances CAR T cell persistence and antitumor activity in solid tumors. Science advances · 9 Oct 2026 PMID 42853935
  2. The SPIZ study: rationale and protocol of a randomized controlled trial to optimize interdisciplinary care of patients following cellular therapy through a digitally supported, cross-regional and cross-sectoral care model. Annals of hematology · 26 Sept 2026 PMID 42799871
  3. Comprehensive microRNA profiling coupled with function-based feature selection reveals a biomarker panel for predicting CAR-T cell exhaustion. Biochemical and biophysical research communications · 10 Sept 2026 PMID 42721859
  4. Enhancing HIV-1-specific CAR-T cell functional activity by treatment with a novel cytokine-based scaffold with IL-15 superagonist and TGF-β-neutralizing activity. Journal of virology · 14 Aug 2026 PMID 42599109
  5. Cystine Restriction Alleviates T-cell Exhaustion and Enhances CAR T-cell Potency. Cancer research · 21 Jul 2026 PMID 42479884
  6. CAR T cells secreting anti-EpCAM bispecific T cell engagers overcome tumor heterogeneity in targeting epithelial-originated carcinomas. Molecular therapy : the journal of the American Society of Gene Therapy · 21 Jul 2026 PMID 42478044
  7. MISSTE: a multiscale integrative spatial simulator for understanding the mechanisms underlying tissue ecosystems. Computers in biology and medicine · 28 Jun 2026 PMID 42365718
  8. Local delivery of GPC3-CAR T cells in a thermosensitive hydrogel enhances antitumor efficacy in hepatocellular carcinoma. International immunopharmacology · 6 Jun 2026 PMID 42250289
CD19 CAR-T in B-Cell Cancer (8)
  1. Outcomes of locally produced donor-derived anti-CD19 chimeric antigen receptor T-cells in relapsed or refractory B-cell acute lymphoblastic leukemia patients. Cancer chemotherapy and pharmacology · 17 Sept 2026 PMID 42752932
  2. Immune checkpoint knockout screen reveals TIGIT-CD155 interaction as a significant modulator of adapter CAR-T cell function in acute myeloid leukemia. Oncoimmunology · 17 Sept 2026 PMID 42750591
  3. Real-world treatment patterns and outcomes of patients treated with commercial chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma. Current medical research and opinion · 26 Aug 2026 PMID 42642985
  4. Long-term outcomes of anti-CD19 CAR T cell therapy in refractory myasthenia gravis: A case series. Cell reports. Medicine · 21 Aug 2026 PMID 42628528
  5. Pretreatment With BTK Inhibitors Improved the Sensitivity of DLBCL Cells to CAR-T Cells in a Coculture System by Downregulating the Polarisation of M2 Macrophages. Journal of cellular and molecular medicine · 30 Jul 2026 PMID 42528053
  6. Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting. British journal of haematology · 6 Jul 2026 PMID 42410301
  7. CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission. Blood advances · 24 Jun 2026 PMID 42341322
  8. In Vivo CAR T-Cell Therapy Spurs 100% ORR in Phase I. Cancer discovery · 9 Jun 2026 PMID 42261652
Tumor Microenvironment Remodeling (7)
  1. An Orthotopic Xenograft Model for Preclinical Evaluation of CAR T Cell Therapy in Glioblastoma. Current protocols · 30 Oct 2026 PMID 42961140
  2. Glioblastoma immune landscape remodeling following treatment with CD70-targeted CAR-T cells. Oncoimmunology · 19 Oct 2026 PMID 42894313
  3. A spatially resolved implantable microdevice for multiplexed in situ screening of engineered cellular therapies in solid tumors. Science advances · 28 Aug 2026 PMID 42664321
  4. Targeting Regnase-1 in B7-H3-CAR T cells reprograms the tumor microenvironment and enhances antitumor efficacy for osteosarcoma. Cell reports. Medicine · 25 Aug 2026 PMID 42641597
  5. Injectable bioinstructive microfoam for rapid bedside/in vivo programming of CAR-T cells. Molecular therapy : the journal of the American Society of Gene Therapy · 18 Jul 2026 PMID 42470101
  6. A radiopharmaceutical enhances CAR T cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling. Cell reports. Medicine · 23 Jun 2026 PMID 42335901
  7. The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM. Cell · 15 Jun 2026 PMID 42296961
CAR-T Efficacy Mechanisms (6)
  1. Tumor cell-intrinsic stress states drive sensitivity to CAR T cell therapy in pancreatic cancer. Science advances · 2 Oct 2026 PMID 42826199
  2. CAR signaling instructs divergent metabolic reprogramming and functional fates in αβ and γδ T cells. Cellular & molecular immunology · 29 Sept 2026 PMID 42811126
  3. CD28-ICOS costimulation enhances the therapeutic efficacy of L1CAM-targeted CAR-T cells against ovarian and gastric cancers. Journal for immunotherapy of cancer · 18 Sept 2026 PMID 42759981
  4. Sequential CD2/CD3/CD28 activation improves nonviral large-payload chimeric antigen receptor knock-in at the T cell receptor α constant locus. Cytotherapy · 1 Sept 2026 PMID 42679594
  5. Targeted attenuation of liver fibrosis using microbubble-enhanced protease-activated receptor 1 chimeric antigen receptor T cells. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 1 Jul 2026 PMID 42385355
  6. CCL19-armed oncolytic adenovirus synergizes with CCR7-expressing CAR-T cells to suppress ovarian tumor growth. International immunopharmacology · 6 Jun 2026 PMID 42250288

By study type

Clinical trials (2)
  1. The SPIZ study: rationale and protocol of a randomized controlled trial to optimize interdisciplinary care of patients following cellular therapy through a digitally supported, cross-regional and cross-sectoral care model. Annals of hematology · 26 Sept 2026 PMID 42799871
  2. CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission. Blood advances · 24 Jun 2026 PMID 42341322
Observational studies and case reports (2)
  1. Outcomes of locally produced donor-derived anti-CD19 chimeric antigen receptor T-cells in relapsed or refractory B-cell acute lymphoblastic leukemia patients. Cancer chemotherapy and pharmacology · 17 Sept 2026 PMID 42752932
  2. Long-term outcomes of anti-CD19 CAR T cell therapy in refractory myasthenia gravis: A case series. Cell reports. Medicine · 21 Aug 2026 PMID 42628528
Human data, design not indexed (4)
  1. Comprehensive microRNA profiling coupled with function-based feature selection reveals a biomarker panel for predicting CAR-T cell exhaustion. Biochemical and biophysical research communications · 10 Sept 2026 PMID 42721859
  2. Enhancing HIV-1-specific CAR-T cell functional activity by treatment with a novel cytokine-based scaffold with IL-15 superagonist and TGF-β-neutralizing activity. Journal of virology · 14 Aug 2026 PMID 42599109
  3. The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM. Cell · 15 Jun 2026 PMID 42296961
  4. In Vivo CAR T-Cell Therapy Spurs 100% ORR in Phase I. Cancer discovery · 9 Jun 2026 PMID 42261652
Preclinical: animal, cell and lab studies (19)
  1. An Orthotopic Xenograft Model for Preclinical Evaluation of CAR T Cell Therapy in Glioblastoma. Current protocols · 30 Oct 2026 PMID 42961140
  2. Glioblastoma immune landscape remodeling following treatment with CD70-targeted CAR-T cells. Oncoimmunology · 19 Oct 2026 PMID 42894313
  3. Extracellular matrix-targeted TNC-scFv armoring enhances CAR T cell persistence and antitumor activity in solid tumors. Science advances · 9 Oct 2026 PMID 42853935
  4. Tumor cell-intrinsic stress states drive sensitivity to CAR T cell therapy in pancreatic cancer. Science advances · 2 Oct 2026 PMID 42826199
  5. CAR signaling instructs divergent metabolic reprogramming and functional fates in αβ and γδ T cells. Cellular & molecular immunology · 29 Sept 2026 PMID 42811126
  6. CD28-ICOS costimulation enhances the therapeutic efficacy of L1CAM-targeted CAR-T cells against ovarian and gastric cancers. Journal for immunotherapy of cancer · 18 Sept 2026 PMID 42759981
  7. Immune checkpoint knockout screen reveals TIGIT-CD155 interaction as a significant modulator of adapter CAR-T cell function in acute myeloid leukemia. Oncoimmunology · 17 Sept 2026 PMID 42750591
  8. Sequential CD2/CD3/CD28 activation improves nonviral large-payload chimeric antigen receptor knock-in at the T cell receptor α constant locus. Cytotherapy · 1 Sept 2026 PMID 42679594
  9. A spatially resolved implantable microdevice for multiplexed in situ screening of engineered cellular therapies in solid tumors. Science advances · 28 Aug 2026 PMID 42664321
  10. Targeting Regnase-1 in B7-H3-CAR T cells reprograms the tumor microenvironment and enhances antitumor efficacy for osteosarcoma. Cell reports. Medicine · 25 Aug 2026 PMID 42641597
  11. Pretreatment With BTK Inhibitors Improved the Sensitivity of DLBCL Cells to CAR-T Cells in a Coculture System by Downregulating the Polarisation of M2 Macrophages. Journal of cellular and molecular medicine · 30 Jul 2026 PMID 42528053
  12. Cystine Restriction Alleviates T-cell Exhaustion and Enhances CAR T-cell Potency. Cancer research · 21 Jul 2026 PMID 42479884
  13. CAR T cells secreting anti-EpCAM bispecific T cell engagers overcome tumor heterogeneity in targeting epithelial-originated carcinomas. Molecular therapy : the journal of the American Society of Gene Therapy · 21 Jul 2026 PMID 42478044
  14. Injectable bioinstructive microfoam for rapid bedside/in vivo programming of CAR-T cells. Molecular therapy : the journal of the American Society of Gene Therapy · 18 Jul 2026 PMID 42470101
  15. Targeted attenuation of liver fibrosis using microbubble-enhanced protease-activated receptor 1 chimeric antigen receptor T cells. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 1 Jul 2026 PMID 42385355
  16. MISSTE: a multiscale integrative spatial simulator for understanding the mechanisms underlying tissue ecosystems. Computers in biology and medicine · 28 Jun 2026 PMID 42365718
  17. A radiopharmaceutical enhances CAR T cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling. Cell reports. Medicine · 23 Jun 2026 PMID 42335901
  18. Local delivery of GPC3-CAR T cells in a thermosensitive hydrogel enhances antitumor efficacy in hepatocellular carcinoma. International immunopharmacology · 6 Jun 2026 PMID 42250289
  19. CCL19-armed oncolytic adenovirus synergizes with CCR7-expressing CAR-T cells to suppress ovarian tumor growth. International immunopharmacology · 6 Jun 2026 PMID 42250288
Unclassified: not yet indexed with MeSH (2)
  1. Real-world treatment patterns and outcomes of patients treated with commercial chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma. Current medical research and opinion · 26 Aug 2026 PMID 42642985
  2. Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting. British journal of haematology · 6 Jul 2026 PMID 42410301